A newly-published real-world study in the Journal of the American College of Clinical Pharmacy finds new data supporting the use of Paxlovid in high-risk COVID-19 patients. The retrospective study followed patients administered the combination therapy at a single medical center, finding that the […]
Medicaid Directors Tell US Congress That Uncertainty around Public Health Emergency Status is Too Much
The uncertainty building around the COVID-19 public health emergency (PHE) in the US is becoming too much for Medicaid to bear, according to a coalition of Medicaid directors. The association told congress that the tenuous status of the Medicaid continuous enrollment requirement during the PHE is […]
Bivalent COVID-19 Boosters Bolster Efficacy of Original Versions, Real-World Data Study Finds
Newly released data from the US Centers for Disease Control and Prevention (CDC) show that patients vaccinated with the new wave of bivalent COVID-19 boosters had better protection than those that have only taken the original versions. Moreover, results from the real-world data (RWD) study show that […]
WHO Draft Pandemic Rules Could Make Pharma Disclose Prices
New draft rules by the World Health Organization (WHO) may force pharma companies to reveal the prices of any drugs under public procurement contracts. This comes after criticism of the industry over a lack of pricing transparency regarding therapeutics like vaccines during the COVID-19 […]
Study Finds Most US Adults Don’t Know About Upcoming Medicare Eligibility Redeterminations
A newly published report from the Robert Wood Johnson Foundation finds that most US adults with a family member on Medicaid are unaware of impending eligibility redeterminations. The redeterminations are set to hit after the COVID-19 public health emergency is ended by the federal government. Many […]
Real-World Evidence Studies Show Efficacy of COVID-19 Therapeutics
Two new real-world evidence studies exploring the efficacy of two treatments for COVID-19 have been published in the British Medical Journal (BMJ). The first study investigated real-world data (RWD) from fully vaccinated high-risk adult patients in England. Those taking sotrovimab had better […]
NICE Makes New Round of COVID-19 Drug Approval Recommendations
The UK’s NICE has announced its recommendations of approval for three COVID-19 drugs and the rejection of five others based on value and efficacy data. Paxlovid, RoActemra, and Olumiant from Pfizer, Roche, and Eli Lilly, respectively, made the cut. Uncertain efficacy data and pricing issues sank the […]
Pfizer Considering 400% COVID-19 Vaccine Price Increase in US
Since their release to the general public last year, the US government has been purchasing and providing COVID-19 vaccines free of charge to patients. With this program set to end soon as public demand for the vaccine draws down, Pfizer is looking to hike its price up by 400% as it enters the […]
Real-World Data Study Gives Look at Merck’s COVID Drug’s Performance After Middling Sales
Merck’s COVID-19 drug Lagrevio has suffered from middling sales since its emergency use authorization last December, with 755,000 of 2.5 million doses used. New real-world data (RWD) from the PANORAMIC study has shown positive results, with patients reporting that it cut average recovery times by 6 […]
Eiger’s Scraps Emergency Use Authorization Submission for COVID-19 Treatment
The US Food and Drug Administration has rejected Eiger BioPharmaceuticals’ request to meet with the agency regarding peginterferon lambda, its repurposed hepatitis D treatment for use in COVID-19. The company asked for the meeting to discuss an emergency use authorization in September based on data […]
